Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia

Endocrinology

Volumn 150, Issue 5, 2009, Pages 2027-2035

  Lozano, Daniel ^a   De Castro, Luis F ^a   Dapia, Sonia ^b   Andrade Zapata, Irene ^a   Manzarbeitia, Felix ^a   Alvarez Arroyo, M Victoria ^a   Gomez Barrena, Enrique ^a   Esbrit, Pedro ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Trabeculae Empresa de Base Tecnologica SL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MANNITOL; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RELATED PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; STREPTOZOCIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; PARATHYROID HORMONE RELATED PEPTIDE (1 36); PARATHYROID HORMONE-RELATED PEPTIDE (1-36); PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE MINERALIZATION; BONE REGENERATION; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; PHENOTYPE; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; ANIMAL; BONE DENSITY; CELL CULTURE; COMPARATIVE STUDY; DIABETES MELLITUS; DOWN REGULATION; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; METABOLIC BONE DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REGENERATION; CELLS, CULTURED; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; GENE EXPRESSION REGULATION; MALE; MICE; OSTEOBLASTS; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; STREPTOZOCIN;

EID: 66449105642     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1108     Document Type: Article

References (56)

1. Carnevale V, Romagnoli E, D'Erasmo E 2004 Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196-204
2. Hofbauer LC, Brueck CC, Singh SK, Dobnig H 2007 Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22:1317-1328
3. Inzerillo AM, Epstein S 2004 Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 5:261-268
4. Inaba M, Okuno S, Nagasue K, Otoshi T, Kurioka Y, Maekawa K, Kumeda Y, Imanishi Y, Ishimura E, Ohta T, Morii H, Kim M, Nishizawa Y 2001 Impaired secretion of parathyroid hormone is coherent to diabetic hemodia- lyzed patients. Am J Kidney Dis 38(Suppl 1):S139-S142
5. Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA 2000 Down-regulation of human osteoblast PTH/ PTHrP receptor mRNA in end-stage renal failure. Kidney Int 58:1440-1449
6. YoshidaO, InabaM, TeradaM, ShioiA, NishizawaY, OtaniS, MoriiH1995 Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 21:201-204
7. Tsuchida T, Sato K, Miyakoshi N, Abe T, Kudo T, Tamura Y, Kasukawa Y, Suzuki K 2000 Histomorphometric evaluation of the recovering effect of human parathyroid hormone (1-34) on bone structure and turnover in strepto- zotocin-induced diabetic rats. Calcif Tissue Int 66:229 -233
8. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA 2003 Teriparatide(human parathyroid hormone(1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 278:50195-50202
9. Suzuki K, Sugimoto C, Takizawa M, Ishizuka S, Kikuyama M, Togawa H, Taguchi Y, Nosaka K, Seino Y, Ishida H 2000 Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res Clin Pract 48:185-191
10. Stewart AF 2002 Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton. J Bone Miner Res 17:758 -762
11. Strewler GJ 2000 The physiology of parathyroid hormone-related protein. N Engl JMed 342:177-185
12. Kartsogiannis V, Moseley J, McKelvie B, Chou ST, Hards DK, NgKW, Martin TJ, Zhou H 1997 Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model. Bone 21:385-392
13. Lomri A, de Pollak C, Sebag M, Goltzman D, Kremer R, Marie PJ 1997 Expression of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in newborn human calvaria osteoblastic cells. Eur JEndocrinol 136: 640 -648
14. Martinez P, Esbrit P, Rodrigo A, Alvarez-Arroyo MV, Martinez ME 2002 Age-related changes in parathyroid hormone-related protein and vascular en- dothelial growth factor in human osteoblastic cells. Osteoporos Int 13:874-881
15. Bisello A, Horwitz MJ, Stewart AF 2004 Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology 145:3551-3553
16. Miao D, He B, Lanske B, Bai XY, Tong XK, Hendy GN, Goltzman D, Karaplis AC 2004 Skeletal abnormalities in Pth-null mice are influenced by dietary calcium. Endocrinology 145:2046-2053
17. Miao D, Li J, Xue Y, Su H, Karaplis AC, Goltzman D 2004 Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology 145:3554-3562
18. Miao D, He B, Jiang Y, Kobayashi T, Soroceanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC 2005 Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. JClin Invest 115:2402-2411
19. Chen HL, Demiralp B, Schneider A, Koh AJ, Silve C, Wang CY, McCauley LK 2002 Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 277: 19374 -19381
20. Carpio L, Gladu J, Goltzman D, Rabbani SA 2001 Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Physiol Endocrinol Metab 281:E489-E499
21. de Gortazar AR, Alonso V, Alvarez-Arroyo MV, Esbrit P 2006 Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endo- thelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 79:360-369
22. Alonso V, de Gortazar AR, Ardura JA, Andrade-Zapata I, Alvarez-Arroyo MV, Esbrit P 2008 Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. J Cell Physiol 217:717-727
23. Maor G, Karnieli E 1999 The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology 140:1841-1851
24. Lu H, Kraut D, Gerstenfeld LC, Graves DT 2003 Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 144:346 -352
25. Botolin S, Fuagere MC, Malluche H, Orth M, Meyer R, McCabe LR 2005 Increased bone adiposity and peroxisomal proliferator-activated receptor-y2 expression in type 1 diabetic mice. Endocrinology 146:3622-3631
26. Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M 2007 Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 40:1408 -1414
27. BotolinS, McCabe LR 2007 Bone loss and increased bone adiposityin spontaneous and pharmacologically induced diabetic mice. Endocrinology 148: 198 -205
28. Okuda N, Takeda S, Shinomiya K, Muneta T, Itoh S, Noda M, Asou Y2007 ED-71, a novel vitamin D analog, promotes bone formation and angio- genesis and inhibits bone resorption after bone marrow ablation. Bone 40:281-292
29. Mattsson G, Carlsson PO, Olausson K, Jansson L 2002 Histological markers for endothelial cells in endogenous and transplanted rodent pancreatic islets. Pancreatology 2:155-162
30. Iida-Klein A, Lu SS, Yokoyama K, Dempster DW, Nieves JW, Lindsay R2003 Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivo. J Clin Densitom 6:25-33
31. Feldkamp LA, Davis LC, Kress JW1984 Practical cone-beam algorithm. JOpt Soc Am A 1:612-619
32. Ulrich D, van Rietbergen B, Laib A, Riiegsegger P 1999 The ability of three- dimensionalstructuralindices to reflectmechanicalaspects oftrabecularbone. Bone 25:55-60
33. Kostenuik PJ, Halloran BP, Morey-Holton ER, Bikle DD 1997 Skeletal unloading inhibits the in vitro proliferation and differentiation of rat osteoprogenitor cells. Am JPhysiol 273(6 Pt 1):E1133-E1139
34. Zayzafoon M, Stell C, Irwin R, McCabe LR 2000 Extracellular glucose influences osteoblast differentiation and c-jun expression. J Cell Biochem 79: 301-310
35. Barbara A, Delannoy P, Denis BG, Marie PJ 2004 Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism 53:532-537
36. Luppen CA, Smith E, Spevak L, Boskey AL, Frenkel B2003 Bonemorphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblastcultures. JBoneMinerRes 18:1186-1197
37. Valin A, Garcia-Ocana A, De Miguel F, Sarasa JL, Esbrit P 1997 Antiprolif- erative effect of the C-terminal fragments of parathyroid hormone-related protein, PTHrP-(107-111) and(107-139), onosteoblasticosteosarcomacells. JCell Physiol 170:209-215
38. McDonald IM, Austin C, Buck IM, Dunstone DJ, Gaffen J, Griffin E, Harper EA, Hull RA, Kalindjian SB, Linney ID, Low CM, Patel D, Pether MJ, Raynor M, Roberts SP, Shaxted ME, Spencer J, Steel KI, Sykes DA, Wright PT, Xun W 2007 Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists. JMed Chem 50:4789-4792
39. Benjamin LE 2001 Glucose, VEGF-A, and diabetic complications. Am J Pathol 158:1181-1184
40. Towler DA 2007 Vascular biologyand bone formation: hints from HIF. JClin Invest 117:1477-1480
41. Jacobsen KA, Al-Aql ZS, Wan C, Fitch JL, Stapleton SN, Mason ZD, Cole RM, Gilbert SR, Clemens TL, Morgan EF, Einhorn TA, Gerstenfeld LC 2008 Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 23:596-609
42. Vaes BL, Ducy P, Sijbers AM, Hendriks JM, van Someren EP, deJong NG, van den Heuvel ER, Olijve W, van Zoelen EJ, Dechering KJ 2006 Microarray analysis on Runx2-deficient mouse embryos reveals novel Runx2 functions and target genes during intramembranous and endochondral bone formation. Bone 39:724-738
43. Schiller PC, D'Ippolito G, Roos BA, Howard GA 1999 Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment. JBone Miner Res 14:1504-1512
44. Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK 2007 Cyclin D1 as a targetfortheproliferativeeffectsofPTHandPTHrPinearlyosteoblasticcells. J Bone Miner Res 22:951-964
45. Celil AB, Hollinger JO, Campbell PG 2005 Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signalling. J Cell Biochem 95:518 -528
46. Botolin S, McCabe LR 2006 Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. JCell Biochem 99:411-424
47. Pfeilschifter J, Diel I, Pilz U, Brunotte K, Naumann A, Ziegler R 1993 Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. JBone Miner Res 8:707-717
48. Esbrit P, Alvarez-Arroyo MV, De Miguel F, Martin O, Martinez ME, Cara- melo C 2000 C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 11:1085-1092
49. Ardura JA, Berruguete R, Ramila D, Alvarez-Arroyo MV, Esbrit P 2008 Parathyroid hormone-related protein interacts with vascular endothelial growth factor to promote fibrogenesis in the obstructed mouse kidney. Am J Physiol Renal Physiol 295:F415-F425
50. Plotkin H, Gundberg C, Mitnick M, Stewart AF 1998 Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83:2786-2791
51. Thomas DM, Hards DK, Rogers SD, Ng KW, Best JD 1996 Insulin receptor expression in bone. J Bone Miner Res 11:1312-1320
52. Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL 2007 Dis-ruptionoftheinsulin-likegrowthfactortype1 receptorinosteoblastsenhances insulin signalling and action. J Biol Chem 282:25649 -25658
53. Fang Y, Wang ZY, Mao Y, Xin HT, Ren GL, Bai XF 2006 Effects of insulinlike growth factor I on the development of osteoblasts in hyperglycemia. Diabetes Res Clin Pract 73:95-97
54. Balint E, Szabo P, Marshall CF, Sprague SM 2001 Glucose-induced inhibition of in vitro bone mineralization. Bone 28:21-28
55. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T 2007 The combination of high glucose and advanced glycation end- products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39:871-875
56. Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y, MoriiH, OtaniS 1998 Growth-inhibitoryeffectofhighglucoseconcentrationonosteoblast-likecells. Bone 22:17-23